Watson Pharmaceuticals Inc. develops, manufactures, and sells proprietary (brand) and off-patent, or generic, pharmaceutical products. The company offers more than 140 generic products as well as 30 branded products marketed through three divisions: general products, nephrology, and women's health. Watson was.
Watson was able to profit, though, because it was often the only company competing in its selected niches. The big drugs, in contrast, were often copied by as many as ten or more generics manufacturers that competed fiercely on price. That tactic allowed the company to utilize its advanced research and development arm to generate relatively high profit margins, even in the generics industry. To find those high-margin, small-market drugs, Watson's researchers regularly plied public records, searching for little-known drug prospects with big potential.
Actavis Generics is a global pharmaceutical company focused on developing, manufacturing and commercializing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products. Actavis has a commercial presence across approximay 100 countries. The company has global headquarters in.
by Watson). Eden Biodesign (Acq.
2014 by Forest). Aptalis Pharma (Eurand Pharmaceuticals & Axcan Pharma merged 2011, Acq.
In 2011, the company moved its corporate headquarters from Corona, California to Parsippany, New Jersey. The new LEED-certified corporate headquarters at the Morris Corporate Center in Parsippany was formally dedicated on June 9, 2011.
Just two months later, the founders established an initial product-development and analytical laboratory with six employees (including both founders) in a leased space in Libertyville, Illinois (U.S.).
24, 2013 /PRNewswire/ -- Watson Pharmaceuticals, Inc. today announced that the company has adopted Actavis, Inc. (NYSE: ACT) as its new global name Actavis Pharma also develops and out-licenses generic pharmaceutical products outside the U.S. through its Medis third-party business, the world's.
Actavis Specialty Brands is the Company's global branded specialty pharmaceutical business, which develops and markets a portfolio of approximay 40 products principally in the United States and Canada that are focused in the Urology and Women's Health therapeutic categories. Actavis Specialty Brands is committed to developing and marketing biosimilars products in Women's Health, Oncology and other therapeutic categories, and currently has a portfolio of 5 biosimilar products in development.
Actavis is the world's third-largest generics prescription drug manufacturer.
The FTC filed its complaint on March 31, 2016, naming as guilty parties Endo Pharmaceuticals Inc, Allergan and its unit Watson Laboratories Inc, Impax Laboratories Inc, Teikoku Seiyaku Co Ltd. and Teikoku Pharma USA Inc. The two drugs at the centre of the complaint are Endo-branded products, Opana being an.
Please use this form to report any data issues. Company data is provided by S&P Global Market Inligence. To contact Watson Laboratories, Inc., please visit --.
Documentation will be required. Only a company representative may request an update for the company profile.
Our data partners will research the update request and update the information on this page if necessary. If you have questions, you can contact them at. Research and follow-up could take several weeks.
For inquiries, please contact S&P Global Market Inligence directly by clicking here.
At Teva Pharmaceutical Industries, we improve people's health through our products, integrated R&D, generic medicines and global businesses.
Teva reports positive results in study for prevention of chronic and episodic migraine.
Teva’s Healthcare Heroes Awards program honors the memory of Richard Egosi, former Teva group EVP and chief legal officer.
Specialized in CNS & Respiratory Cutting-edge R&D.
Your browser does not support iframes.
See what we’re doing and where.
Teva releases 2016 Social Impact report Teva Names Kåre Schultz.
Kåre Schultz joins Teva as President and CEO.
as President and CEO.
Teva announces new organization structure and leadership changes.
Major advance in the development of new treatment options for millions of patients Teva's Fremanezumab.